FDA throws up another roadblock to Cardiome, 9 years after rejecting its drug
Nine years after the FDA threw Cardiome $CRME for a loop, rejecting its IV atrial fibrillation drug Brinavess (vernakalant), the biotech is no closer to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
